Get the Stockscreener App
0.76
4.11%
0.03
Pre-market:
.78
0.02
+2.63%
InspireMD Inc. stock is traded at $0.76, with a volume of 599.99K.
It is up +4.11% in the last 24 hours and down -27.62% over the past month.
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms in order to seal the aneurysms. InspireMD, Inc. distributes its products in Europe, Latin America, the Middle East, and Asia. The company is headquartered in Tel Aviv, Israel.
See More
Previous Close:
$0.73
Open:
$0.78
24h Volume:
599.99K
Relative Volume:
2.27
Market Cap:
$35.60M
Revenue:
$10.85M
Net Income/Loss:
$-51.31M
P/E Ratio:
-1.0312
EPS:
-0.737
Net Cash Flow:
$-40.15M
1W Performance:
-6.90%
1M Performance:
-27.62%
6M Performance:
-61.42%
1Y Performance:
-67.24%
1-Day Range:
$0.69
$0.888
1-Week Range:
$0.69
$0.888
52-Week Range:
$0.69
$2.9319
InspireMD Inc. Stock (NSPR) Company Profile
Name
InspireMD Inc.
Sector
Industry
Phone
972 3 6917691
Address
4 Menorat Hamaor Street, Tel Aviv
Compare NSPR vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NSPR
InspireMD Inc.
|
0.76 | 35.60M | 10.85M | -51.31M | -40.15M | -0.737 |
ABT
Abbott Laboratories
|
88.67 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.94 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
80.38 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
46.76 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.28 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
InspireMD Inc. Stock (NSPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-26 | Initiated | Maxim Group | Buy |
| Jan-07-16 | Initiated | Rodman & Renshaw | Buy |
| Mar-13-15 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-26-13 | Initiated | Oppenheimer | Outperform |
InspireMD Inc. Stock (NSPR) Latest News
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - marketscreener.com
InspireMD announces inducement grants - Medical Buyer
NSPR Q1 2026 Earnings: EPS Beat Surprises on Strong Cost ManagementCore Business Growth - newsline.com
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Six new InspireMD employees receive 91,161-share stock grants - Stock Titan
InspireMD, Inc. (NSPR) reports Q1 loss, tops revenue estimates - MSN
InspireMD Reports Strong 30-Day Results From CGUARDIANS II Trial - TipRanks
Stroke-prevention stent hits 100% success in 50 high-risk patients - Stock Titan
InspireMD (NSPR) reports 100% device success in TCAR trial - Stock Titan
InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures - marketscreener.com
NSPR Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
NSPR Q1 2026 Earnings: EPS Surprises to the Upside Amid Limited Revenue VisibilityPost-Earnings Drift - newsline.com
InspireMD Initiates CGUARDIANS III Study for SwitchGuard Neuro Protection System in TCAR Procedures - Quiver Quantitative
InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures - GlobeNewswire
NSPR Q1 2026 Earnings: EPS Surprise of 12.85% Highlights Cost Discipline Amid Pre‑Revenue Stage - newsline.com
NSPR News | INSPIREMD INC (NASDAQ:NSPR) - ChartMill
InspireMD (NSPR) holders OK 250M authorized shares, re-elect directors - Stock Titan
InspireMD NSPR Q1 2026 Earnings Transcript - The Globe and Mail
NSPR Q1 2026 Earnings: EPS Surprises to the Upside, Stock Reacts PositivelyEstimate Revision Count - thelegaladvocate.com
InspireMD director Paul Stuka buys $17,500 in shares By Investing.com - Investing.com Australia
InspireMD (NSPR) Inches Higher as Shares Approach Key Resistance at $0.97Gap and Go - thelegaladvocate.com
InspireMD director Paul Stuka buys $17,500 in shares - Investing.com
Director Paul Stuka buys 20,000 InspireMD (NSPR) shares in open-market trade - Stock Titan
InspireMD (NSPR) Gains 6% to $0.95 as Stock Approaches Critical $1.00 ResistanceHigh Conviction Picks - newsline.com
InspireMD anticipates FDA approval of original CGuard delivery system in Q3 2026 as it withdraws 2026 revenue guidance - MSN
InspireMD Inc. (NSPR) Q1 2026 Earnings: Narrower Loss Than Expected But Shares SlideEarnings Call Highlights - thelegaladvocate.com
InspireMD (NSPR) Slides 7.9% as Stock Tests Key Support Near $0.84RVOL Spike - The Legal Advocate
InspireMD (NSPR) Slides 8.4% to $0.87: Key Levels Under PressureEarnings Beat Stocks - newsline.com
InspireMD (NSPR) Q1 2026 Earnings: EPS Beat Despite Net Loss, Shares Dip 2.9%Post-Announcement Reaction - Newser
Paul Stuka to Retire from InspireMD Board, Will Not Seek Re‑election - TradingView
InspireMD (NSPR) chair Paul Stuka plans Board retirement in 2027 - Stock Titan
NSPR Q1 2026 Earnings: Loss Narrower Than Expected as InspireMD Advances Commercial PipelineProfit Growth Outlook - Newser
InspireMD CCO Shane Gleason sells $189,594 in stock By Investing.com - Investing.com Canada
InspireMD CCO Shane Gleason sells $189,594 in stock - Investing.com
InspireMD (NSPR) CCO auto-sells shares to cover RSU tax obligations - Stock Titan
InspireMD (NSPR) price target decreased by 13.33% to 4.42 - MSN
Nantahala reports 4.82M shares in InspireMD (NSPR) including convertibles - Stock Titan
Director Stuka increases InspireMD (NSPR) stake with 15,000-share buys - Stock Titan
Velan Capital holds 4.99% of InspireMD (NASDAQ: NSPR) via 2.35M shares - Stock Titan
TradingKey - TradingKey
InspireMD CEO Marvin Slosman buys $25,200 in company stock By Investing.com - Investing.com Australia
InspireMD Inc (NSPR) CEO Marvin Slosman Increases Stake with Rec - GuruFocus
NSPR: Endovascular stenting for carotid disease is accelerating, backed by best-in-class clinical results - TradingView
InspireMD CEO Marvin Slosman buys $25,200 in company stock - Investing.com UK
InspireMD Inc. Stock (NSPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):